News briefing: AstraZeneca follows Amgen down KRAS/SHP2 combo path; Vallon Pharmaceuticals files for $17 million IPO
Revolution Medicines is adding AstraZeneca to its roster of clinical collaborators, lending its lead drug, RMC-4630, for a study pairing it with the pharma giant’s KRAS G12C program.
AstraZeneca will sponsor and conduct the study once its now preclinical drug is ready for human studies, an arrangement similar to the deal Revolution has with Amgen on sotorasib.
“Drug combinations are likely to be critical for defeating inherent drug resistance mechanisms exploited by RAS-addicted cancers,” CEO Mark Goldsmith said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.